Bicara Therapeutics Inc. Common Stock (BCAX) - Total Liabilities
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has total liabilities worth $43.48 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BCAX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Bicara Therapeutics Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BCAX total assets.
Bicara Therapeutics Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
agilon health Inc
NYSE:AGL
|
USA | $1.36 Billion |
|
CEAT Limited
NSE:CEATLTD
|
India | Rs88.48 Billion |
|
Métropole Télévision S.A.
PA:MMT
|
France | €651.90 Million |
|
Savaria Corporation
TO:SIS
|
Canada | CA$458.82 Million |
|
Farglory Land Development Co Ltd
TW:5522
|
Taiwan | NT$64.70 Billion |
|
Beijing Lanxum Tech Co
SHE:300010
|
China | CN¥740.98 Million |
|
Global Blue Group Holding Ltd
NYSE:GB
|
USA | $1.03 Billion |
|
Avi Ltd
JSE:AVI
|
South Africa | ZAC5.15 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Bicara Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Bicara Therapeutics Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bicara Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Bicara Therapeutics Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.54 Million | -61.79% |
| 2024-12-31 | $77.32 Million | +399.68% |
| 2023-12-31 | $15.47 Million | -35.47% |
| 2022-12-31 | $23.98 Million | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more